Table 3. Consensus for translational research.

Priority	Issues
High	Diagnostic reliability of PD-L1 tests on cytological samples and small biopsies
	PD-L1 levels on liquid biopsy
	Biomarkers of tumor foreignness
	Mechanisms of resistance in PD-L1 positive tumors
	Mechanisms of responsiveness in PD-L1 negative tumors
Moderate	Development of common strategies to detect at the RNA level gene fusion (ALK, ROS1, RET) and immune signature biomarkers
	Archival versus rebiopsy specimens for PD-L1 expression
	Heterogeneity of PD-L1 expression in primary versus metastatic sites
Low	Influence of prior treatments on PD-L1 expression
	Evaluation of the role of PD-L1 expression in NSCLC versus other solid tumors
	Correlation between PD-L1 expression and other driver mutations

PD-L1, programmed death-ligand 1; NSCLC, non-small cell lung cancer.